The oligonucleotide therapy market has witnessed rapid expansion, increasing from $4.9 billion in 2023 to $5.61 billion in 2024, at a CAGR of 14.4%. This growth is driven by R&D investment, early therapies, and advancements in gene editing. The market is expected to reach $8.75 billion by 2028, at a CAGR of 11.8%. Key factors include expansion into new therapeutic areas and regulatory adaptations. Trends include customized therapies, RNA interference, and gene editing techniques.
Major Driver In The Oligonucleotide Therapy Market
The oligonucleotide therapy market is expected to witness growth driven by the rising incidence of cancer cases worldwide. According to the American Cancer Society, the US is projected to see approximately 1.9 million new cancer diagnoses and over 609,000 cancer-related deaths in 2022. Lung, prostate, bowel, and female breast cancer collectively account for 43% of all new cancer cases globally. The escalating cancer incidence rates underscore the urgent need for effective treatment modalities, driving demand for oligonucleotide therapy. As cancer continues to pose a significant healthcare challenge globally, the oligonucleotide therapy market is poised to expand to address the growing demand for innovative cancer treatment options.
Request A Free Sample Of The Global Oligonucleotide Therapy Market Report
Oligonucleotide Therapy Market Competitive Landscape
Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Gelead Sciences Inc., BioNTech SE, Moderna Inc., Biogen Inc., Bausch + Lomb Company, Jazz Pharmaceuticals plc, QIAGEN Company, Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Dynavax Technologies Corp., Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals lnc., SomaGenics Inc., Wave Life Sciences Ltd., Exicure Inc., Hepion Phrmaceuticals lnc., Avidity Biosciences lnc., Miragen Therapeuutics Inc., ProQR Therapeutics NV, Regulus Therapeutics Inc., PCI Biotech Holdings ASA, Kastle Therapeutics LLC, Santaris Pharma A/S, InteRNA Technologies B.V., Dynacure S.A., Arcturus Therapeutics Holdings Inc., Intellia Therapeutics Inc., Regeneron Pharmaceuticals Inc., Editas Medicine Inc., Evox Therapeutics Ltd., ONK Therapeutics Ltd., PepGen Ltd.
Key Oligonucleotide Therapy Market Trend
The developers and providers of the oligonucleotide therapy market are investing in research and development to remodel the design of therapy to reduce its side effects on patients. The new and innovative oligonucleotides allow for precision medicine approaches and can be designed to selectively target any gene with minimal side effects. It also helps in targeting patient-specific sequences that are causative of rare diseases. In April 2023, the FDA approved Qalsody, an antisense oligonucleotide (ASO), for the treatment of patients with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene. Qalsody targets SOD1 mRNA to reduce the synthesis of SOD1 protein
Get The Full Global Oligonucleotide Therapy Market Report
Oligonucleotide Therapy Market Segmentation
The oligonucleotide therapy market covered in this report is segmented –
1) By Type: Antisense Oligonucleotide, Aptamer, Other Types
2) By Application: Infectious Diseases, Oncology, Neurodegenerative Disorders, Cardiovascular Diseases, Kidney Diseases, Other End-User
3) By End User: Hospitals, Research Institutes
By Geography:The regions covered in the oligonucleotide therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
North America was the largest region in the oligonucleotide therapy market in 2023.
The Oligonucleotide Therapy Global Market Report 2024 furnishes information about the global oligonucleotide therapy market, encompassing details like market size, projections for growth, segmentation across various sectors and regions, and an overview of competitors, including their revenues, profiles, and market shares. Furthermore, the report pinpoints potential opportunities and strategic directions derived from market trends and the strategies adopted by key competitors. The report also offers an assessment of how the COVID-19 pandemic, the Russia-Ukraine conflict, and increasing inflation have affected both global and regional markets, furnishing valuable strategic insights for businesses.
